# A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate

> **NCT00845832** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 24 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** rituximab [MabThera/Rituxan]
- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT00845832
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The study was terminated early because of a related decision to stop the development of ocrelizumab in rheumatoid arthritis.
- **Last updated:** 2014-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00845832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00845832, "A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00845832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*